The relationship between Bordetella pertussis genotype and clinical severity in Australian children with pertussis - 29/01/16


Summary |
Objectives |
Changes in circulating Bordetella pertussis genotypes, including a novel pertussis toxin promoter ptxP3 allele and absence of pertactin (Prn) antigen, have been reported from several countries but limited data on relative severity are available. We compared markers of disease severity in children with B. pertussis infection due to strains of differing genotype.
Methods |
Culture confirmed cases presenting to tertiary paediatric hospitals in three Australian states between 2008 and 2012 were classified as severe if they required a hospital stay greater than seven days, were admitted to intensive care, or if death occurred. Associations between age, vaccination, genotype and severity were assessed.
Results |
Of 199 pertussis cases, 81 (41%) were <3 months, including 32/39 (82%) of severe cases. The proportion of isolates from these cases that were Prn deficient increased markedly between 2008 and 2012. Of B. pertussis isolates, the proportion considered severe was similar for Prn positive (27/128, 21%) and Prn deficient (12/71, 17%) cases but only 1/22 (4.5%) of non ptxP3 cases were severe versus 38/177 (21.4%) ptxP3 positive. Adjusting for ptxP type, vaccination status and age, disease severity was not significantly associated with Prn status (RRA: 0.95, [0.57–1.56]; p = 0.83).
Conclusions |
In children, we found no relationship between Prn status and markers of severe pertussis. An increased proportion of severe disease in isolates with the ptxP3 allele was observed.
Le texte complet de cet article est disponible en PDF.Highlights |
• | Prn deficient isolates were not associated with pertussis severity. |
• | Almost all isolates from severe pertussis cases carried the ptxP3 allele. |
• | The majority of severe pertussis occurred in infants <3 months of age. |
• | Young age and absence of prior vaccination were related to severe pertussis. |
Keywords : Pertussis, Hospitalization, Children, Pertactin, Severity
Plan
☆ | Conference presentation: This research has been presented in part at the Communicable Diseases Control Conference, Brisbane Australia, 01 Jun 2015. Abstract ID #137. |
Vol 72 - N° 2
P. 171-178 - février 2016 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?